Drugs /

codrituzumab

Back to Drugs List

Overview

NCI Definition [1]:
A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell death. GPC3, a heparin sulfate proteoglycan, is frequently upregulated in hepatocellular carcinoma and mesoderm-derived organs such as the liver, lungs, and kidney.

Clinical Trials

View Clinical Trials for codrituzumab

Codrituzumab has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating codrituzumab, 1 is phase 1 (1 open).

GPC3 Expression is the most frequent biomarker inclusion criterion for codrituzumab clinical trials.

Hepatoblastoma and malignant solid tumor are the most common diseases being investigated in codrituzumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Codrituzumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating codrituzumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-gpc3 monoclonal antibody gc33, anti-glypican 3 monoclonal antibody gc33, gc33, anti-glypican 3 monoclonal antibody gc33, gc-33, rg 7686, ro 5137382, ro-5137382, ro5137382
Drug Target(s) [2]:
GPC3
NCIT ID [1]:
C80043

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.